[2000/01 influenza season and the vaccine composition for the season 2001/'02]. 2001

J C de Jong, and G F Rimmelzwaan, and A I Bartelds, and B Wilbrink, and R A Fouchier, and A D Osterhaus
Erasmus Universiteit, afd. Virologie, Postbus 1738, 3000, DR Rotterdam. jc.de.jong@wxs.nl

In the 2000/01 season, the size of the influenza epidemic in the Netherlands was exceptionally small. Since the start of the Continuous Morbidity Registration of the Netherlands Institute of Primary Health Care (NIVEL) in 1970, the peak incidence of influenza-like illnesses has never been so low. The aetiology of the epidemic was also unusual. Most remarkable was the relatively extensive circulation of subtype H1N1 and the low activity of subtype H3N2. The epidemic started in week 1 of 2001 and ended in week 8. The antigenic properties of the influenza A (H1N1) viruses closely resembled those of the vaccine strain A/New Caledonia/20/99. This new variant of subtype H1N1 was first isolated in Asia in 1995 and was only (sporadically) detected in the Netherlands in the 1999/2000 season. Phylogenetic analysis showed that these viruses represent a new line of subtype H1N1. Following the influenza-activity caused by H1N1 viruses in the 2000/01 season, a small number of B and H3N2 viruses were also isolated up to week 19. Antigenically, these viruses were identical to those obtained in the previous years. On the basis of the antigenetic analyses presented, it can be concluded that the vaccine provided good protection against the circulating influenza viruses in the 2000/01 season. The World Health Organization recommends that influenza vaccines intended for use in the 2001/02 season of the northern hemisphere should contain the following, or antigenically similar, strains: A/Moscow/10/99 (H3N2), A/New Caledonia/20/99 (H1N1), and B/Sichuan/379/99.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D009426 Netherlands Country located in EUROPE. It is bordered by the NORTH SEA, BELGIUM, and GERMANY. Constituent areas are Aruba, Curacao, and Sint Maarten, formerly included in the NETHERLANDS ANTILLES. Holland,Kingdom of the Netherlands
D009980 Influenza A virus The type species of the genus ALPHAINFLUENZAVIRUS that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces. Alphainfluenzavirus influenzae,Avian Orthomyxovirus Type A,FLUAV,Fowl Plague Virus,Human Influenza A Virus,Influenza Virus Type A,Influenza Viruses Type A,Myxovirus influenzae-A hominis,Myxovirus influenzae-A suis,Myxovirus pestis galli,Orthomyxovirus Type A,Orthomyxovirus Type A, Avian,Orthomyxovirus Type A, Human,Orthomyxovirus Type A, Porcine,Pestis galli Myxovirus,Fowl Plague Viruses,Influenza A viruses,Myxovirus influenzae A hominis,Myxovirus influenzae A suis,Myxovirus, Pestis galli,Myxoviruses, Pestis galli,Pestis galli Myxoviruses,Plague Virus, Fowl,Virus, Fowl Plague
D009981 Influenza B virus Species of the genus BETAINFLUENZAVIRUS that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed. Betainfluenzavirus influenzae,FLUBV,Human Influenza B Virus,Influenza Viruses Type B,Influenza virus type B,Orthomyxoviruses Type B,Influenza B viruses
D011159 Population Surveillance Ongoing scrutiny of a population (general population, study population, target population, etc.), generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than by complete accuracy. Surveillance, Population
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014943 Global Health A multi- and interdisciplinary field concerned with improving health and achieving equity in health for all people. It transcends national boundaries, promotes cooperation and collaboration within and beyond health science fields, and combines population-based disease prevention with individually-based patient care. International Health Problems,World Health,International Health,Worldwide Health,Health Problem, International,Health Problems, International,Health, Global,Health, International,Health, World,Health, Worldwide,Healths, International,International Health Problem,International Healths,Problem, International Health,Problems, International Health

Related Publications

J C de Jong, and G F Rimmelzwaan, and A I Bartelds, and B Wilbrink, and R A Fouchier, and A D Osterhaus
June 2001, MMWR. Morbidity and mortality weekly report,
J C de Jong, and G F Rimmelzwaan, and A I Bartelds, and B Wilbrink, and R A Fouchier, and A D Osterhaus
July 2001, JAMA,
J C de Jong, and G F Rimmelzwaan, and A I Bartelds, and B Wilbrink, and R A Fouchier, and A D Osterhaus
May 2000, MMWR. Morbidity and mortality weekly report,
J C de Jong, and G F Rimmelzwaan, and A I Bartelds, and B Wilbrink, and R A Fouchier, and A D Osterhaus
December 2000, Vaccine,
J C de Jong, and G F Rimmelzwaan, and A I Bartelds, and B Wilbrink, and R A Fouchier, and A D Osterhaus
June 2002, MMWR. Morbidity and mortality weekly report,
J C de Jong, and G F Rimmelzwaan, and A I Bartelds, and B Wilbrink, and R A Fouchier, and A D Osterhaus
December 2001, MMWR. Morbidity and mortality weekly report,
J C de Jong, and G F Rimmelzwaan, and A I Bartelds, and B Wilbrink, and R A Fouchier, and A D Osterhaus
March 2003, Emerging infectious diseases,
J C de Jong, and G F Rimmelzwaan, and A I Bartelds, and B Wilbrink, and R A Fouchier, and A D Osterhaus
January 2001, MMWR. Morbidity and mortality weekly report,
J C de Jong, and G F Rimmelzwaan, and A I Bartelds, and B Wilbrink, and R A Fouchier, and A D Osterhaus
December 2000, MMWR. Morbidity and mortality weekly report,
J C de Jong, and G F Rimmelzwaan, and A I Bartelds, and B Wilbrink, and R A Fouchier, and A D Osterhaus
February 2002, Canada communicable disease report = Releve des maladies transmissibles au Canada,
Copied contents to your clipboard!